US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Silexion Therapeutics Corp

0.2773

-0.0411-12.91%

Post-market: 0.29020.0129+4.65%19:58 EDT

Volume:11.60M

Turnover:3.08M

Market Cap:1.60M

PE:0.00

High:0.2773

Open:0.2632

Low:0.2560

Close:0.3184

52wk High:42.60

52wk Low:0.2362

Shares:5.76M

Float Shares:5.67M

Volume Ratio:0.17

T/O Rate:204.50%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-56.4473

EPS(LYR):-89.5962

ROE:-897.46%

ROA:-123.27%

PB:36.28

PE(LYR):0.00

Loading ...

Overview Company News Filings

Immunotherapy’s Biggest Blind Spot Is a $7 Billion Market. Silexion May Have a Way In (NASDAQ: SLXN)

Silexion Therapeutics Publishes Corporate Deck Spotlighting Sil204 siRNA Program Targeting KRAS-Driven Cancers

Silexion Therapeutics files to sell ordinary shares, warrants, no amount given

Silexion Reports Preclinical Sil204 Data Supporting Phase 2/3 Development in KRAS-Driven Cancers

Silexion Therapeutics Corp - Announces Positive Preclinical Findings for Sil204 in Kras-Mutant Cancer Cells

THOMSON REUTERS

Silexion Therapeutics Director Amnon Peled Resigns for Personal Reasons

Silexion Activates First Site in Phase 2/3 Trial Targeting KRAS-Driven Pancreatic Cancer (NASDAQ: SLXN)

Silexion Therapeutics Successfully Initiates Phase 2/3 Clinical Trial of Sil204 in Locally Advanced Pancreatic Cancer at Tel Aviv Sourasky Medical Center

THOMSON REUTERS

Silexion Therapeutics Corp - Additional Israeli and German Sites Expected to Join Sil204 Phase 2/3 Trial in Coming Months

THOMSON REUTERS

Silexion Therapeutics Corp - Receives All Regulatory Approvals for Sil204 Trial in Israel as of July 29, 2026

THOMSON REUTERS

Silexion Therapeutics Shareholders Raise Authorized Share Capital Via Memorandum Amendment

Analysts Are Bullish on Top Healthcare Stocks: Silexion Therapeutics (SLXN), Viking Therapeutics (VKTX)

Silexion Therapeutics Corp : Maxim Group Adjusts Target Price to $6 From $60 to Reflect 1-for-10 Reverse Stock Split

THOMSON REUTERS

Silexion wins Germany BfArM clearance to launch SIL204 Phase 2/3 pancreatic cancer trial

Silexion Therapeutics Corp - to Initiate Phase 2/3 Trial of Sil204 in Israel and Germany

THOMSON REUTERS

Silexion Therapeutics Corp - Trial Approved Without Conditions Following Positive Ethics Committee Opinion in Germany

THOMSON REUTERS

Silexion Therapeutics presentation highlights SIL204 siRNA program targeting KRAS-driven pancreatic cancer

Silexion Therapeutics management to attend BIO International Convention 2026

Silexion Therapeutics files to sell 859,609 ordinary shares for holders

Silexion Therapeutics executes 1-for-10 reverse share split

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg1.tigeractivity.com/stock/SLXN/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"SLXN","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SLXN\",,,,,undefined,":{"symbol":"SLXN","market":"US","secType":"STK","nameCN":"Silexion Therapeutics Corp","latestPrice":0.2773,"timestamp":1790798400000,"preClose":0.3184,"halted":0,"volume":11599694,"hourTrading":{"tag":"盘后","latestPrice":0.2902,"preClose":0.2773,"latestTime":"19:58 EDT","volume":1017214,"amount":285766.347675,"timestamp":1790812724617,"change":0.0129,"changeRate":0.04652,"amplitude":0.088352},"delay":0,"changeRate":-0.1290829145728644,"floatShares":5672255,"shares":5755900,"eps":-56.4473,"marketStatus":"Not Yet Opened","change":-0.0411,"latestTime":"09-30 16:00:00 EDT","open":0.26315,"high":0.2773,"low":0.256,"amount":3079656.58264016,"amplitude":0.066897,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-56.4473,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1790841600000},"marketStatusCode":0,"adr":0,"exchange":"NASDAQ","adjPreClose":0.3184,"preHourTrading":{"tag":"盘前","latestPrice":0.2634,"preClose":0.3184,"latestTime":"09:29 EDT","volume":1688712,"amount":453003.10713744006,"timestamp":1790774994275,"change":-0.055,"changeRate":-0.172739,"amplitude":0.131595},"postHourTrading":{"tag":"盘后","latestPrice":0.2902,"preClose":0.2773,"latestTime":"19:58 EDT","volume":1017214,"amount":285766.347675,"timestamp":1790812724617,"change":0.0129,"changeRate":0.04652,"amplitude":0.088352},"volumeRatio":0.167701},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SLXN\",,,,,undefined,":{"symbol":"SLXN","floatShares":5672255,"roa":"-123.27%","roe":"-897.46%","lyrEps":-89.596245,"volumeRatio":0.167701,"shares":5755900,"dividePrice":0,"high":0.2773,"amplitude":0.066897,"preClose":0.3184,"low":0.256,"week52Low":0.2362,"pbRate":"36.28","week52High":42.6,"institutionHeld":0,"latestPrice":0.2773,"eps":-56.4473,"divideRate":0,"volume":11599694,"delay":0,"ttmEps":-56.4473,"open":0.26315,"prevYearClose":19.2,"prevWeekClose":0.2603,"prevMonthClose":0.3697,"prevQuarterClose":2.55,"fiveDayClose":0.3153,"twentyDayClose":0.3701,"sixtyDayClose":2.74},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/SLXN\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-05-29","symbol":"SLXN","defaultRemindTime":1780061400000,"type":"split","dateTimestamp":1780027200000,"forFactor":10,"toFactor":1,"ratio":10},{"market":"US","date":"2025-07-29","symbol":"SLXN","defaultRemindTime":1753795800000,"type":"split","dateTimestamp":1753761600000,"forFactor":15,"toFactor":1,"ratio":15},{"market":"US","date":"2024-11-29","symbol":"SLXN","defaultRemindTime":1732890600000,"type":"split","dateTimestamp":1732856400000,"forFactor":9,"toFactor":1,"ratio":9},{"market":"US","date":"2024-08-13","symbol":"SLXN","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1723521600000,"reportTimeType":"","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"SLXN\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"SLXN\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":0.5,"hold":0.5,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.5,"analysts":2,"updateTime":1785384000000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/SLXN\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"SLXN","date":"2026-09-29","current":-0.00487,"percent":0.820225,"low":-1.070842,"twenty":-0.515839,"median":-0.247343,"eighty":-0.10264,"high":-0.012403,"avg":-0.320379,"sd":0.238799,"marketCap":1381167},"quantilePoints":[{"date":"2025-05-02","current":-0.511745,"twenty":-0.505522,"median":-0.478123,"eighty":-0.462658,"marketCap":8414615},{"date":"2025-05-09","current":-0.508623,"twenty":-0.511745,"median":-0.504017,"eighty":-0.475134,"marketCap":8363285},{"date":"2025-05-16","current":-0.49368,"twenty":-0.511295,"median":-0.503966,"eighty":-0.488849,"marketCap":8117579},{"date":"2025-05-23","current":-0.504427,"twenty":-0.509135,"median":-0.49826,"eighty":-0.470682,"marketCap":8294286},{"date":"2025-05-30","current":-0.491275,"twenty":-0.511407,"median":-0.49826,"eighty":-0.475032,"marketCap":8078030},{"date":"2025-06-06","current":-0.471573,"twenty":-0.511407,"median":-0.49368,"eighty":-0.475196,"marketCap":7754067},{"date":"2025-06-13","current":-0.453201,"twenty":-0.509647,"median":-0.491403,"eighty":-0.471409,"marketCap":7451983},{"date":"2025-06-20","current":-0.41963,"twenty":-0.506945,"median":-0.488844,"eighty":-0.464552,"marketCap":6899984},{"date":"2025-06-27","current":-0.415025,"twenty":-0.504283,"median":-0.484008,"eighty":-0.449824,"marketCap":6824252},{"date":"2025-07-03","current":-0.415025,"twenty":-0.504048,"median":-0.478123,"eighty":-0.41963,"marketCap":6824252},{"date":"2025-07-11","current":-0.42265,"twenty":-0.503966,"median":-0.474592,"eighty":-0.417174,"marketCap":6949630},{"date":"2025-07-18","current":-0.440049,"twenty":-0.503178,"median":-0.468758,"eighty":-0.415025,"marketCap":7235727},{"date":"2025-07-25","current":-0.430889,"twenty":-0.49932,"median":-0.464408,"eighty":-0.415332,"marketCap":7085105},{"date":"2025-08-01","current":-0.509697,"twenty":-0.49932,"median":-0.462719,"eighty":-0.415332,"marketCap":8380951},{"date":"2025-08-08","current":-0.292718,"twenty":-0.495931,"median":-0.452101,"eighty":-0.414513,"marketCap":4813156},{"date":"2025-08-15","current":-0.251096,"twenty":-0.493608,"median":-0.447572,"eighty":-0.409037,"marketCap":4128768},{"date":"2025-08-22","current":-0.231991,"twenty":-0.492964,"median":-0.436237,"eighty":-0.386752,"marketCap":3814623},{"date":"2025-08-29","current":-0.263889,"twenty":-0.49148,"median":-0.430786,"eighty":-0.303498,"marketCap":4339133},{"date":"2025-09-05","current":-0.238814,"twenty":-0.491275,"median":-0.423383,"eighty":-0.280777,"marketCap":3926818},{"date":"2025-09-12","current":-0.168193,"twenty":-0.491275,"median":-0.420859,"eighty":-0.25246,"marketCap":2765601},{"date":"2025-09-19","current":-0.12316,"twenty":-0.486413,"median":-0.417583,"eighty":-0.247343,"marketCap":2025116},{"date":"2025-09-26","current":-0.128618,"twenty":-0.486106,"median":-0.415793,"eighty":-0.244955,"marketCap":2114871},{"date":"2025-10-03","current":-0.128618,"twenty":-0.484008,"median":-0.415025,"eighty":-0.242737,"marketCap":2114871},{"date":"2025-10-10","current":-0.136465,"twenty":-0.48104,"median":-0.413413,"eighty":-0.231991,"marketCap":2243896},{"date":"2025-10-17","current":-0.121454,"twenty":-0.478123,"median":-0.409651,"eighty":-0.138853,"marketCap":1997067},{"date":"2025-10-24","current":-0.114972,"twenty":-0.478123,"median":-0.401489,"eighty":-0.132201,"marketCap":1890482},{"date":"2025-10-31","current":-0.112584,"twenty":-0.477611,"median":-0.386196,"eighty":-0.129301,"marketCap":1851214},{"date":"2025-11-07","current":-0.097914,"twenty":-0.471573,"median":-0.312505,"eighty":-0.127936,"marketCap":1609995},{"date":"2025-11-14","current":-0.097914,"twenty":-0.471163,"median":-0.292718,"eighty":-0.123842,"marketCap":1609995},{"date":"2025-11-21","current":-0.080173,"twenty":-0.468758,"median":-0.272333,"eighty":-0.121795,"marketCap":1318288},{"date":"2025-11-28","current":-0.096549,"twenty":-0.467039,"median":-0.257237,"eighty":-0.120362,"marketCap":1587556},{"date":"2025-12-05","current":-1.070842,"twenty":-0.471245,"median":-0.259284,"eighty":-0.119953,"marketCap":9902075},{"date":"2025-12-12","current":-1.0279,"twenty":-0.478706,"median":-0.282158,"eighty":-0.120362,"marketCap":9504991},{"date":"2025-12-19","current":-0.821644,"twenty":-0.486167,"median":-0.30227,"eighty":-0.120704,"marketCap":7597740},{"date":"2025-12-26","current":-0.797975,"twenty":-0.491377,"median":-0.316599,"eighty":-0.121181,"marketCap":7378875},{"date":"2026-01-02","current":-0.6492,"twenty":-0.495368,"median":-0.386196,"eighty":-0.12159,"marketCap":6003152},{"date":"2026-01-09","current":-0.710063,"twenty":-0.504027,"median":-0.401489,"eighty":-0.122205,"marketCap":6565948},{"date":"2026-01-16","current":-0.825025,"twenty":-0.510588,"median":-0.409651,"eighty":-0.122955,"marketCap":7629006},{"date":"2026-01-23","current":-0.726969,"twenty":-0.515839,"median":-0.412313,"eighty":-0.12316,"marketCap":6722280},{"date":"2026-01-30","current":-0.662725,"twenty":-0.574408,"median":-0.414769,"eighty":-0.123296,"marketCap":6128218},{"date":"2026-02-06","current":-0.510569,"twenty":-0.606596,"median":-0.415025,"eighty":-0.12391,"marketCap":4721229},{"date":"2026-02-13","current":-0.534237,"twenty":-0.597129,"median":-0.417327,"eighty":-0.124456,"marketCap":4940094},{"date":"2026-02-20","current":-0.534237,"twenty":-0.591719,"median":-0.41963,"eighty":-0.125548,"marketCap":4940094},{"date":"2026-02-27","current":-0.588338,"twenty":-0.588338,"median":-0.42265,"eighty":-0.127254,"marketCap":5440357},{"date":"2026-03-06","current":-0.557906,"twenty":-0.584956,"median":-0.42723,"eighty":-0.127936,"marketCap":5158959},{"date":"2026-03-13","current":-0.563418,"twenty":-0.591719,"median":-0.432424,"eighty":-0.128618,"marketCap":5209923},{"date":"2026-03-20","current":-0.377654,"twenty":-0.588338,"median":-0.436237,"eighty":-0.128618,"marketCap":4498612},{"date":"2026-03-27","current":-0.366297,"twenty":-0.584956,"median":-0.430786,"eighty":-0.128959,"marketCap":4363328},{"date":"2026-04-02","current":-0.341131,"twenty":-0.584956,"median":-0.423383,"eighty":-0.129233,"marketCap":4063557},{"date":"2026-04-10","current":-0.310374,"twenty":-0.584956,"median":-0.420859,"eighty":-0.131075,"marketCap":3697171},{"date":"2026-04-17","current":-0.279616,"twenty":-0.584956,"median":-0.417583,"eighty":-0.131655,"marketCap":3330785},{"date":"2026-04-24","current":-0.257275,"twenty":-0.583604,"median":-0.415793,"eighty":-0.131962,"marketCap":3064655},{"date":"2026-05-01","current":-0.171153,"twenty":-0.571093,"median":-0.415025,"eighty":-0.132167,"marketCap":2038773},{"date":"2026-05-08","current":-0.145121,"twenty":-0.564344,"median":-0.413413,"eighty":-0.133702,"marketCap":1728677},{"date":"2026-05-15","current":-0.139472,"twenty":-0.562336,"median":-0.409651,"eighty":-0.135442,"marketCap":1661395},{"date":"2026-05-22","current":-0.12255,"twenty":-0.558738,"median":-0.40296,"eighty":-0.131962,"marketCap":1582122},{"date":"2026-05-29","current":-0.138778,"twenty":-0.557906,"median":-0.397852,"eighty":-0.132133,"marketCap":1791622},{"date":"2026-06-05","current":-0.160977,"twenty":-0.557906,"median":-0.386196,"eighty":-0.133327,"marketCap":2078215},{"date":"2026-06-12","current":-0.100286,"twenty":-0.557906,"median":-0.370491,"eighty":-0.132133,"marketCap":1294694},{"date":"2026-06-18","current":-0.09412,"twenty":-0.552496,"median":-0.356785,"eighty":-0.130188,"marketCap":1215085},{"date":"2026-06-26","current":-0.088602,"twenty":-0.543705,"median":-0.341131,"eighty":-0.128209,"marketCap":1143856},{"date":"2026-07-02","current":-0.083896,"twenty":-0.541677,"median":-0.338335,"eighty":-0.124456,"marketCap":1083102},{"date":"2026-07-10","current":-0.084708,"twenty":-0.536943,"median":-0.320891,"eighty":-0.122887,"marketCap":1093576},{"date":"2026-07-17","current":-0.090225,"twenty":-0.534237,"median":-0.31317,"eighty":-0.120908,"marketCap":1164806},{"date":"2026-07-24","current":-0.077243,"twenty":-0.534237,"median":-0.309392,"eighty":-0.118588,"marketCap":997208},{"date":"2026-07-31","current":-0.059717,"twenty":-0.534237,"median":-0.302127,"eighty":-0.117019,"marketCap":770950},{"date":"2026-08-07","current":-0.058095,"twenty":-0.534237,"median":-0.293597,"eighty":-0.113607,"marketCap":750001},{"date":"2026-08-14","current":-0.014929,"twenty":-0.532214,"median":-0.288004,"eighty":-0.102349,"marketCap":192737},{"date":"2026-08-21","current":-0.158944,"twenty":-0.532214,"median":-0.280777,"eighty":-0.100286,"marketCap":2218542},{"date":"2026-08-28","current":-0.143488,"twenty":-0.530856,"median":-0.278246,"eighty":-0.101584,"marketCap":2002804},{"date":"2026-09-04","current":-0.140062,"twenty":-0.527475,"median":-0.263889,"eighty":-0.102008,"marketCap":1954986},{"date":"2026-09-11","current":-0.168305,"twenty":-0.527475,"median":-0.257275,"eighty":-0.102281,"marketCap":2349208},{"date":"2026-09-18","current":-0.151375,"twenty":-0.523078,"median":-0.251778,"eighty":-0.106989,"marketCap":2112897},{"date":"2026-09-25","current":-0.102377,"twenty":-0.517885,"median":-0.247684,"eighty":-0.106995,"marketCap":1428985},{"date":"2026-09-29","current":-0.098952,"twenty":-0.515839,"median":-0.247343,"eighty":-0.10264,"marketCap":1381167}],"updateTime":1790798343528},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"SLXN\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2658372956","title":"Immunotherapy’s Biggest Blind Spot Is a $7 Billion Market. Silexion May Have a Way In (NASDAQ: SLXN)","url":"https://stock-news.laohu8.com/highlight/detail?id=2658372956","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658372956?lang=en_us&edition=fundamental","pubTime":"2026-08-11 03:30","pubTimestamp":1786390213,"startTime":"0","endTime":"0","summary":"WSW, NY, August 10th, 2026, FinanceWire Checkpoint inhibitors are drugs that remove the “brakes” cancer puts on the immune system, letting the body...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/newswire/immunotherapys-biggest-blind-spot-is-a-7-billion-market-silexion-may-have-a-way-in-nasdaq-slxn?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/newswire/immunotherapys-biggest-blind-spot-is-a-7-billion-market-silexion-may-have-a-way-in-nasdaq-slxn?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["JEPQ","NVIW.SI","ONEQ","QYLG","SQQQ","MNQmain","NDX","NQmain","TQQQ","QID",".IXIC","PSQ","QQQM","IYW","QLD","QQQJ","QQQ","TECS","TQQY","SLXN","GPIQ","QQQE","FTEC","QQQA","BK4139","QDTE","QQQY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658672068","title":"Silexion Therapeutics Publishes Corporate Deck Spotlighting Sil204 siRNA Program Targeting KRAS-Driven Cancers","url":"https://stock-news.laohu8.com/highlight/detail?id=2658672068","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658672068?lang=en_us&edition=fundamental","pubTime":"2026-08-09 20:41","pubTimestamp":1786279307,"startTime":"0","endTime":"0","summary":"Silexion Therapeutics publishes corporate deck spotlighting SIL204 siRNA program targeting KRAS-driven cancersSilexion highlighted SIL204, a second-generation siRNA designed to silence KRAS expression","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260809:nNDL4dLvQl:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLXN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657629937","title":"Silexion Therapeutics files to sell ordinary shares, warrants, no amount given","url":"https://stock-news.laohu8.com/highlight/detail?id=2657629937","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657629937?lang=en_us&edition=fundamental","pubTime":"2026-08-08 04:45","pubTimestamp":1786135543,"startTime":"0","endTime":"0","summary":"16:40 EDT Silexion Therapeutics (SLXN) files to sell ordinary shares, warrants, no amount given Published first on TheFly – the ultimate source for...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/silexion-therapeutics-files-to-sell-ordinary-shares-warrants-no-amount-given-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/silexion-therapeutics-files-to-sell-ordinary-shares-warrants-no-amount-given-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SLXN","BK4539","BK4007","LENZ","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656559067","title":"Silexion Reports Preclinical Sil204 Data Supporting Phase 2/3 Development in KRAS-Driven Cancers","url":"https://stock-news.laohu8.com/highlight/detail?id=2656559067","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656559067?lang=en_us&edition=fundamental","pubTime":"2026-08-04 21:16","pubTimestamp":1785849372,"startTime":"0","endTime":"0","summary":"Silexion reports preclinical SIL204 data supporting Phase 2/3 development in KRAS-driven cancersSilexion Therapeutics reported new preclinical results for SIL204, extending earlier findings disclosed ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260804:nNDL3xJwvC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0314104364.USD","IE00BN0W2V16.EUR","BCDF","IE00BN0W2T93.GBP","IE00B64PRP62.GBP","SG9999014013.SGD","IE00B3QW5Z07.USD","BK4585","SLXN","BK4139","IE00BGHQF748.EUR","IE00BN0W2W23.USD","BK4588","SG9999014039.USD","LU2210150020.SGD","NDAQ","BK4112","LU2095319765.USD","SG9999014005.SGD","IE00BKPKM429.USD","SG9999014021.USD","LU2210149790.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656559706","title":"Silexion Therapeutics Corp - Announces Positive Preclinical Findings for Sil204 in Kras-Mutant Cancer Cells","url":"https://stock-news.laohu8.com/highlight/detail?id=2656559706","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656559706?lang=en_us&edition=fundamental","pubTime":"2026-08-04 21:15","pubTimestamp":1785849330,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260804:nFWN4411EJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SLXN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656996183","title":"Silexion Therapeutics Director Amnon Peled Resigns for Personal Reasons","url":"https://stock-news.laohu8.com/highlight/detail?id=2656996183","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656996183?lang=en_us&edition=fundamental","pubTime":"2026-08-01 04:07","pubTimestamp":1785528442,"startTime":"0","endTime":"0","summary":"Silexion Therapeutics director Amnon Peled resigns for personal reasonsProfessor Amnon Peled resigned from the board of Silexion Therapeutics for personal reasons, effective Aug. 1, 2026.The resignati","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260731:nNDL11FsMv:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SLXN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655895299","title":"Silexion Activates First Site in Phase 2/3 Trial Targeting KRAS-Driven Pancreatic Cancer (NASDAQ: SLXN)","url":"https://stock-news.laohu8.com/highlight/detail?id=2655895299","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655895299?lang=en_us&edition=fundamental","pubTime":"2026-07-29 21:30","pubTimestamp":1785331817,"startTime":"0","endTime":"0","summary":"WSW, NY, July 29th, 2026, FinanceWire Silexion Therapeutics (NASDAQ:SLXN) just announced that it initiated its Phase 2/3 clinical trial of SIL204 a...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/newswire/silexion-activates-first-site-in-phase-2-3-trial-targeting-kras-driven-pancreatic-cancer-nasdaq-slxn?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/newswire/silexion-activates-first-site-in-phase-2-3-trial-targeting-kras-driven-pancreatic-cancer-nasdaq-slxn?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["JEPQ","MNQmain","QQQ","QQQA","SQQQ","QQQM","NVIW.SI","QID","SLXN","TQQQ","IYW","FTEC","GDOC","QQQE","NQmain","QYLG","IDNA","TECS","TQQY","HYLG","QDTE","QQQY","NVIB","BK4139","GPIQ","ONEQ","PSQ","QQQJ","NDX","QLD",".IXIC","MEDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655864843","title":"Silexion Therapeutics Successfully Initiates Phase 2/3 Clinical Trial of Sil204 in Locally Advanced Pancreatic Cancer at Tel Aviv Sourasky Medical Center","url":"https://stock-news.laohu8.com/highlight/detail?id=2655864843","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655864843?lang=en_us&edition=fundamental","pubTime":"2026-07-29 19:00","pubTimestamp":1785322802,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260729:nTUA584Y51:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SLXN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655861089","title":"Silexion Therapeutics Corp - Additional Israeli and German Sites Expected to Join Sil204 Phase 2/3 Trial in Coming Months","url":"https://stock-news.laohu8.com/highlight/detail?id=2655861089","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655861089?lang=en_us&edition=fundamental","pubTime":"2026-07-29 19:00","pubTimestamp":1785322802,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260729:nTUA584Y51:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SLXN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655861009","title":"Silexion Therapeutics Corp - Receives All Regulatory Approvals for Sil204 Trial in Israel as of July 29, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2655861009","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655861009?lang=en_us&edition=fundamental","pubTime":"2026-07-29 19:00","pubTimestamp":1785322802,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260729:nTUA584Y51:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SLXN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653788904","title":"Silexion Therapeutics Shareholders Raise Authorized Share Capital Via Memorandum Amendment","url":"https://stock-news.laohu8.com/highlight/detail?id=2653788904","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653788904?lang=en_us&edition=fundamental","pubTime":"2026-07-22 04:12","pubTimestamp":1784664775,"startTime":"0","endTime":"0","summary":"Silexion Therapeutics shareholders raise authorized share capital via memorandum amendmentSilexion Therapeutics shareholders backed an amendment to its Cayman Islands memorandum, lifting authorized sh","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260721:nNDL3M2RXp:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLXN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646178028","title":"Analysts Are Bullish on Top Healthcare Stocks: Silexion Therapeutics (SLXN), Viking Therapeutics (VKTX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2646178028","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646178028?lang=en_us&edition=fundamental","pubTime":"2026-06-25 00:50","pubTimestamp":1782319815,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Silexion Therapeutics (SLXN) and Viking Therapeutics...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-silexion-therapeutics-slxn-viking-therapeutics-vktx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-silexion-therapeutics-slxn-viking-therapeutics-vktx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","VKTX","BK4588","BK4585","BK4599","SLXN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645649028","title":"Silexion Therapeutics Corp : Maxim Group Adjusts Target Price to $6 From $60 to Reflect 1-for-10 Reverse Stock Split","url":"https://stock-news.laohu8.com/highlight/detail?id=2645649028","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645649028?lang=en_us&edition=fundamental","pubTime":"2026-06-24 13:39","pubTimestamp":1782279551,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260624:nFWN42V0WH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SLXN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645836065","title":"Silexion wins Germany BfArM clearance to launch SIL204 Phase 2/3 pancreatic cancer trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2645836065","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645836065?lang=en_us&edition=fundamental","pubTime":"2026-06-23 20:40","pubTimestamp":1782218419,"startTime":"0","endTime":"0","summary":"Silexion won unconditional clearance from Germany’s BfArM to start its Phase 2/3 trial of SIL204 in locally advanced pancreatic cancer.The authorization positions the company to launch the study in Germany alongside previously secured approval in Israel.First patient dosing is expected in the coming weeks, subject to site activation timelines.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260623:nNDL7RcXSq:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210149790.SGD","IE00B64PRP62.GBP","IE00BGHQF748.EUR","SLXN","SG9999014021.USD","BK4139","SG9999014039.USD","IE00BKPKM429.USD","IE00BN0W2V16.EUR","IE00BN0W2W23.USD","IE00B3QW5Z07.USD","IE00BN0W2T93.GBP","NDAQ","BK4112","BK4585","SG9999014013.SGD","BK4588","LU0314104364.USD","LU2210150020.SGD","LU2095319765.USD","SG9999014005.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645836053","title":"Silexion Therapeutics Corp - to Initiate Phase 2/3 Trial of Sil204 in Israel and Germany","url":"https://stock-news.laohu8.com/highlight/detail?id=2645836053","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645836053?lang=en_us&edition=fundamental","pubTime":"2026-06-23 20:40","pubTimestamp":1782218400,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260623:nTUA6641FH:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SLXN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645360558","title":"Silexion Therapeutics Corp - Trial Approved Without Conditions Following Positive Ethics Committee Opinion in Germany","url":"https://stock-news.laohu8.com/highlight/detail?id=2645360558","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645360558?lang=en_us&edition=fundamental","pubTime":"2026-06-23 20:40","pubTimestamp":1782218400,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260623:nTUA6641FH:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SLXN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645022179","title":"Silexion Therapeutics presentation highlights SIL204 siRNA program targeting KRAS-driven pancreatic cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2645022179","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645022179?lang=en_us&edition=fundamental","pubTime":"2026-06-22 20:38","pubTimestamp":1782131887,"startTime":"0","endTime":"0","summary":"Silexion outlined SIL204, an siRNA designed to silence KRAS gene expression with dual delivery targeting primary pancreatic tumors and micrometastases.Program focus is locally advanced pancreatic cancer; KRAS mutations cited in 92% of cases, with SIL204 targeting more than 74% of PDAC KRAS mutations.Total addressable market estimate for localized advanced pancreatic cancer: U.S. about USD 2 billion; E.U. about USD 3 billion.Phase 2/3 trial plan: safety run-in to start mid-2026 with completion expected in Q2 2027; Phase 2 expansion to start Q3 2027.Phase 3 confirmatory segment targeted to start Q3 2030; interim results flagged for 2028 with potential sample size adjustment.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Silexion Therape","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260622:nNDLbrnMYL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLXN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644760946","title":"Silexion Therapeutics management to attend BIO International Convention 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2644760946","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644760946?lang=en_us&edition=fundamental","pubTime":"2026-06-17 04:30","pubTimestamp":1781641857,"startTime":"0","endTime":"0","summary":"Silexion Therapeutics management will attend the 2026 BIO International Convention in San Diego on June 22-25.One-on-one meetings with management are scheduled during the convention.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260616:nNDLrPyMR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","LU2095319765.USD","IE00B64PRP62.GBP","SG9999014013.SGD","BK4588","BK4112","SLXN","BK4139","IE00BKPKM429.USD","SG9999014039.USD","IE00BN0W2V16.EUR","LU2210149790.SGD","IE00BGHQF748.EUR","SG9999014021.USD","IE00B3QW5Z07.USD","IE00BN0W2W23.USD","LU2210150020.SGD","SG9999014005.SGD","NDAQ","IE00BN0W2T93.GBP","LU0314104364.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643218270","title":"Silexion Therapeutics files to sell 859,609 ordinary shares for holders","url":"https://stock-news.laohu8.com/highlight/detail?id=2643218270","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643218270?lang=en_us&edition=fundamental","pubTime":"2026-06-13 04:10","pubTimestamp":1781295049,"startTime":"0","endTime":"0","summary":"16:08 EDT Silexion Therapeutics (SLXN) files to sell 859,609 ordinary shares for holders Published first on TheFly – the ultimate source for real-t...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/silexion-therapeutics-files-to-sell-859609-ordinary-shares-for-holders-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/silexion-therapeutics-files-to-sell-859609-ordinary-shares-for-holders-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","LENZ","BK4539","BK4139","SLXN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639621796","title":"Silexion Therapeutics executes 1-for-10 reverse share split","url":"https://stock-news.laohu8.com/highlight/detail?id=2639621796","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2639621796?lang=en_us&edition=fundamental","pubTime":"2026-05-29 19:02","pubTimestamp":1780052564,"startTime":"0","endTime":"0","summary":"Silexion Therapeutics set a 1-for-10 reverse share split, effective May 28, 2026, subject to board confirmation tied to Nasdaq bid-price compliance.Authorized share capital to be consolidated to US$796,500 divided into 5,900,000 ordinary shares with a par value of US$0.135.Issued ordinary shares to consolidate to 407,471 from 4,074,710, based on the April 7, 2026 share count.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Silexion Therapeutics Corp. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 29, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260529:nNDL4LfKm2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SLXN"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":2,"totalSize":58,"code":"91000000","status":"200"}]}}